
Cancer Therapy Tislelizumab Shows Early Efficacy Signs in Phase 2 Trial Immuno-Oncology News
BeiGene’s investigational anti-PD-1 inhibitor tislelizumab is well-tolerated and showed early signs of efficacy in patients with advanced nasopharyngeal cancer, …
